CliffBio
biologic

Fibryga

Fibrinogen (Human)

Loss of exclusivityJune 2029projected — 12-year biologic exclusivity estimate
CompanyOctapharma Pharmazeutika Produktionsges.m.b.H.

Drug detail

Brand nameFibryga
Active ingredientFibrinogen (Human)
Strength1G
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2017
Marketing statusRx

More from Octapharma Pharmazeutika Produktionsges.m.b.H.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Fibryga patent cliff — loss of exclusivity June 2029 | CliffBio